The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
Pratley
Richard E
RE
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000517:prevention & control*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone